NCT00131066已完成不适用
Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 20
研究概览
简要总结
The purpose of this study is to evaluate the long-term safety and profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507.
详细描述
This study will evaluate the long-term safety and lymphocyte repletion profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507. Patients must have had an ALC > 30% lower than baseline (defined as baseline prior to any MEDI-507 exposure); or an absolute CD4 count of < 250 cells/uL. This study will also evaluate the development and durability of anti-MEDI-507 antibodies.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has previously completed participation (i.e., completed per protocol, including any long term follow-up; or discontinued from the study due to withdrawal of consent, loss to follow-up, or other reason) in a Medimmune, Inc. study of MEDI-507 in psoriasis in which they received MEDI-507 (or placebo for patients who participated in a blinded placebo-controlled study of MEDI-507, and for whom the treatment assignment in that study has not been unblinded at the time of entry into this study)
- •The patient had an absolute lymphocyte count (ALC) > 30% lower than baseline (defined as baseline prior to any MEDI-507 exposure; or, for patients whose treatment assignments have not been unblinded at the time of entry into this study, drug exposure) at his/her final visit (excluding any long-term follow-up visits) in the most recent Medimmune, Inc. study in which the patient participated; or the patient had an absolute CD4 count of < 250 cells/uL at his/her final visit (including any protocol-specific long-term follow up) in the most recent Medimmune, Inc. study in which the patient participated.
- •Written informed consent obtained from the patient
排除标准
- •There are no exclusion criteria.
研究者
研究点 (20)
Loading locations...
相似试验
招募中
不适用
Swiss Dermatology Network of Targeted Therapies (SDNTT)PsoriasisNCT01706692Swiss Dermatology Network for Targeted Therapies1,121
进行中（未招募）
2 期
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisPlaque PsoriasisNCT05739435Alumis Inc165
已完成
1 期
A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque PsoriasisPlaque PsoriasisNCT02435342Kineta Inc.24
已完成
不适用
Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel FormulationPsoriasis VulgarisPlaque PsoriasisNCT01707368LEO Pharma561
已完成
不适用
Comparative Effectiveness of Psoriasis Treatments on Systemic InflammationPsoriasisInflammationNCT02330380University Hospitals Cleveland Medical Center26